News and Press Releases
SeaBeLife secures €2 million
This funding will help fast-track the launch of clinical trials in dry AMD and severe acute hepatitis programs 1 October 2025 -- Roscoff, France -- SeaBeLife, a biotechnology company developing...
Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: October 1, 2025
Pooled data presented at ERS: nerandomilast monotherapy linked to nominally significant reduction in risk of death in IPF and PPF
A new pooled analysis of the FIBRONEER-IPF and FIBRONEER-ILD trials resulted in a nominally significant reduction in the risk of death by 59% in patients who received 18mg nerandomilast without...
Category: Clinical Trials, Drug Delivery, Drug Discovery, Other, Pharmaceutical
Posted: September 29, 2025
Leqembi (lecanemab) long-term 36-month open-label extension data from post-hoc sub-group analysis of ApoE ε4 non-carriers and heterozygotes presented at Alzheimer’s disease congress in Switzerland
Clarity AD open-label extension data show three years of continuous lecanemab treatment in apolipoprotein E ε4 (ApoE ε4) non-carrier and heterozygote patients continued to accrue benefit relative to the Alzheimer's...
Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: September 29, 2025
Chiesi Completes Clinical Development Program for Carbon-Minimal Pressurized Metered-Dose Inhalers (pMDIs), Paving the Way for Regulatory Submissions
Successfully completed the TRECOS Phase III study, supporting the long-term safety of Chiesi’s carbon minimal pressurized metered dose inhaler (pMDI) platform Aiming to become the first pharmaceutical company to transition...
Category: Clinical Trials, Drug Delivery, Other, Pharmaceutical
Posted: September 26, 2025
Lonza’s Synaffix Collaborates with Qurient Therapeutics to Enable Development of Dual-Payload ADC
License agreement centered around technology enabling dual-payload ADC Unique combination of Synaffix’s exatecan-based technology with Qurient’s CDK7 inhibitor. 25 September 2025 -- Amsterdam, The Netherlands and Seongnam-Si, Korea -- Synaffix B.V.,...
Category: Biotechnology, Clinical Trials, Other, Pharmaceutical
Posted: September 25, 2025
Pivot Park, Curie Building Kloosterstraat 9 5349 AB Oss The Netherlands
OKYO Pharma Announces Registration Pathway with 100 Patient Multi-Center Clinical Trial of Urcosimod in Neuropathic Corneal Pain
22 September 2025 -- London, UK and New York, US -- OKYO Pharma Limited, an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod to treat neuropathic corneal pain (NCP), an ocular...
Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: September 22, 2025
Ryvu Therapeutics Announces Strategic Agreement to Support Clinical Trials for BioNTech’s Investigational Cancer Immunotherapies in Poland
Ryvu to support BioNTech in the acceleration of site activation and enrollment of patients for multiple of BioNTech’s priority oncology clinical programs in Poland Ryvu will leverage its clinical network to...
Category: BioManufacturing, Biotechnology, Clinical Trials, Drug Discovery, Pharmaceutical
Posted: September 2, 2025
R&D Center for Innovative Drugs Leona Henryka Sternbacha 2 30-394 Kraków, Poland
Aptamer Group Introduces Novel Biomarker Discovery Service
Accelerated platform delivers validated biomarkers with ready-to-use Optimer ligands in months rather than years Biomarkers are identified based on their ability to translate to drug development strategies. 28 August 2025...
Category: Biotechnology, Drug Discovery, Other, Pharmaceutical
Posted: August 28, 2025
Aptamer group, Suite 2.80 – 2.87, Bio Centre, Innovation Way, Heslington, York, YO10 5NY
Anocca Raises SEK 440 Million to Advance Clinical Trial Targeting Pancreatic Cancer
Financing supports execution of early-stage clinical trials for Anocca’s lead programme VIDAR-1, powered by the Company’s leading-edge R&D platform, to target pancreatic cancer VIDAR-1 is the first non-viral gene-edited TCR-T...
Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: August 18, 2025
Tiziana Life Sciences Doses First Patient in Phase 2a Trial of Intranasal Foralumab for Multiple System Atrophy
BOSTON, Aug. 14, 2025 -- Tiziana Life Sciences, Ltd (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human,...
Category: Clinical Trials
Posted: August 14, 2025
Tiziana Life Sciences 14/15 Conduit Street London W1S 2XJ United Kingdom
Sanofi’s rilzabrutinib earns orphan designation in the EU for IgG4-related disease
Paris, August 14, 2025: The European Medicines Agency has granted orphan designation to rilzabrutinib, a reversible covalent Bruton’s tyrosine kinase (BTK) inhibitor, for IgG4-related disease (IgG4-RD). EMA grants orphan designation...
Category: Clinical Trials
Posted: August 14, 2025
Iksuda Therapeutics receives FDA IND clearance for IKS014
FDA decision will enable Iksuda to expand its ongoing clinical trial in the US, Australia and Singapore Preliminary data from an ongoing dose-escalation study of IKS014 has shown meaningful clinical activity across...
Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: July 1, 2025
Oxeltis and academic partners receive grant funding worth nearly €800,000 to develop antiviral for Bunyaviricetes
France’s National Research Agency (ANR) and Defense Innovation Agency (AID) will finance BUNYANTIVIR project to introduce novel therapeutic approach for Bunyaviricetes class of human pathogenic viruses found in tropical and...
Category:
Posted: June 25, 2025
Novo Nordisk A/S: Ozempic receives EU recommendation in peripheral arterial disease, cementing the broad benefits of semaglutide for people with type 2 diabetes and comorbidities
Pending a decision from the European Commission, Ozempic (once-weekly semaglutide) will have the broadest approved label in the glucagon-like peptide-1 receptor agonist (GLP-1 RA) class, demonstrating improvements in blood sugar,...
Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: June 23, 2025
Kite’s CAR T-Cell Therapy Data Show Real-World Patient Benefit and Durable Response Across Difficult-to-Treat Blood Cancers
Largest Real-World (RW) Analyses of Yescarta® (Axicabtagene Ciloleucel) Show 74% Overall Survival (OS) at 12 Months in Second-Line Relapsed/Refractory Large B-cell Lymphoma (LBCL), Consistent with OS Reported in Pivotal ZUMA-7 Study,...
Category: Biotechnology, Clinical Trials, Drug Delivery, Drug Discovery, Other, Pharmaceutical
Posted: June 12, 2025
